Avamed Synergy, a company led by Lucas Diez (CEO and founder) and based in Alicante, specifically in the technological center of Distrito Digital, has achieved: 800,000 euros in the first stage of the investment round for your project FluxAs reported by the company itself.
Founded in 2010 dedicated firm technology transfer to the healthcare sector formalized the capital increase required for this round, which remains open and will conclude in the next first quarter of 2024 if the company’s planned targets are met. In this way, by reaching the target budget, move forward with your strategic plan to position itself as a leading company in precision medicine and in this context medical imaging.
Fluxus projects enable a clinical study session with a unique host-tumor interface, thanks to the use of Artificial Intelligence and local algorithms. type and subtype of the tumor, its aggressiveness and evolution and ultimately the opportunity to choose the most appropriate treatment for the patient. Additionally, the tool has successfully passed previous clinical studies and is currently in use. pilot and evaluation phase. If the results are positive, it may allow marketing approval.
The group of investors who trusted and invested in this project could not get past this stage, even though they have extensive experience in the world of venture capital and together contributed 500,000 euros in the current round. ENISA and reaching the global figure of 800,000 euros in this first phase. In the coming 2024, Avamed Sinerji will continue to welcome other investors and investment vehicles interested in financing this project.
Thanks to this milestone, the company will expand its staff with new research professionals and continue to work to obtain the necessary health certifications for entry into the European healthcare market.
Lucas Diez, CEO of Avamed Synergy, is confident that the Fluxus tool will revolutionize highly complex surgeries: “With Fluxus, Avamed Synergy is positioning itself as a leading company in technological and digital transformation. Detection, evolution and treatment in complex oncological diagnosis. “By making significant investments in R&D and active participation in innovation in the medical community, Avamed Synergy is making a tangible difference in patients’ lives and the future of personalized medicine.”